Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

167
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
167
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

162
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
162
The Micturition Reflex01:26

The Micturition Reflex

606
Urination, or micturition involves the coordination of the bladder's detrusor muscle and two sphincters to ensure controlled bladder emptying.
The process begins with bladder filling, where the bladder wall stretches as urine accumulates. This stretching activates the urine storage reflex, mediated by the sacral spinal segments and the pontine storage center. Efferent sympathetic impulses stimulate the detrusor muscle to relax and the internal urethral sphincter to contract, facilitating...
606
Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

438
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
438
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

746
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
746
Drug Therapy01:28

Drug Therapy

43
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
43

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Development of a core set of outcome measures for OAB treatment.

International urogynecology journal·2017
Same author

Clinical application of IUGA/ICS classification system for mesh erosion.

Neurourology and urodynamics·2015
Same author

Periurethral aggressive angiomyxoma: a case report.

International urogynecology journal·2012
查看所有相关文章

相关实验视频

Updated: Jun 30, 2025

Detrusor Underactivity Model in Rats by Conus Medullaris Transection
03:26

Detrusor Underactivity Model in Rats by Conus Medullaris Transection

Published on: August 28, 2020

2.1K

过度活跃的膀 药物 获取 获取

Yanghee Courbron1, Caroline Foust-Wright

  • 1From the Maine Medical Partners, Pelvic Medicine and Reconstructive Surgery, South, Portland, ME.

Urogynecology (Philadelphia, Pa.)
|March 14, 2024
PubMed
概括
此摘要是机器生成的。

改善获得过度活性膀药物的机会至关重要. 一个成本导航指南改善了患者对处方治疗的坚持,证明了解决财务障碍的影响.

更多相关视频

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models
10:19

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models

Published on: August 9, 2012

19.3K
Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology
10:26

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

Published on: August 18, 2014

26.3K

相关实验视频

Last Updated: Jun 30, 2025

Detrusor Underactivity Model in Rats by Conus Medullaris Transection
03:26

Detrusor Underactivity Model in Rats by Conus Medullaris Transection

Published on: August 28, 2020

2.1K
Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models
10:19

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models

Published on: August 9, 2012

19.3K
Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology
10:26

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

Published on: August 18, 2014

26.3K

科学领域:

  • 泌尿和妇科 泌尿和妇科
  • 药物经济学 药物经济学
  • 患者的坚持 患者的坚持

背景情况:

  • 过度活性膀 (OAB) 药物在成本,保险覆盖和副作用概况方面存在很大差异.
  • 患者获得和坚持OAB药物治疗往往受到财务和后勤障碍的阻碍.
  • 一项旨在提高患者获得和遵守首选OAB药物的质量改善计划.

研究的目的:

  • 在学术泌尿科医疗实践中,每月从39.5%增加到45%的患者接受他们喜欢的OAB药物的比例.
  • 识别和解决药物获取和持久性障碍在过度活跃膀的患者.
  • 评估针对性干预对改善药物获取和服药的效果的影响.

主要方法:

  • 通过电子健康记录 (Epic),图表审查和患者/药房电话收集了有关药物获取和服药的数据.
  • 开发并实施了成本导航指南,以帮助患者管理处方费用.
  • 干预涉及将指南嵌入到电子健康记录中的访问后摘要中.
  • 进行了干预前后分析,以评估药物持续性的变化.

主要成果:

  • 对OAB药物获取的主要障碍被确定为成本,包括缺乏保险覆盖和未能启动事先授权.
  • 在干预之前,超过60%的患者在6个月内停止了最初处方的OAB药物.
  • 在实施成本导航指南后,在3个月的随访间隔内,药物持续性改善到45.5%.

结论:

  • 专注于处方成本导航的有针对性的干预措施可以显著改善患者获得和持久使用过度活性膀药物.
  • 开发的成本导航指南在缓解OAB药物治疗的财务障碍方面被证明是有效的.
  • 该诊所继续使用处方导航手册来支持患者遵守和获得护理.